Example: tourism industry

Pharmacy and Therapeutics Committee-approved …

Pharmacy and Therapeutics Committee-approvedTherapeutic InterchangesTherapeutic InterchangeRevision DateAlpha Blockers08/11 Alpha Reductase Inhibitors05/16 ACE Inhibitors08/11 Angiotensin Receptor Blockers08/11 Buprenorphine09/11 Calcium Channel Blockers (DHP)08/11 Carbapenems07/11 Cardioselective Beta Blockers08/11 Cephalosporins09/11 Corticosteroids, Inhaled06/16 Corticosteroids, Intranasal08/11 Fluoroquinolones01/13 Glitazones08/11 Histamine Receptor Antagonists (H2 RAs)08/11 Inhaled Anticholinergics05/16 Insulin Analogs05/16IV to PO conversions05/16 Leukotriene Receptor Antagonists08/11 Levalbuterol12/13 Miscellaneous Antidepressants05/16 Miscellaneous CNS Stimulants05/16 Nitroglycerin Sublingual05/16 Non-benzodiazepine Hypnotics08/11 Non-sedating Antihistamines08/11 Ophthalmic Preparations08/11 Phosphate Binders01/13 Proton Pump Inhbitors08/11 Statins08/11 All conversions unless noted otherwise are for adult patients with normal renal and/or hepatic function.

Pharmacy and Therapeutics Committee-approved Therapeutic Interchanges Therapeutic Interchange Revision Date Alpha Blockers …

Tags:

  Committees, Pharmacy, Therapeutic, Approved, Interchange, Pharmacy and therapeutics committee approved, Pharmacy and therapeutics committee approved therapeutic interchanges

Information

Domain:

Source:

Link to this page:

Please notify us if you found a problem with this document:

Other abuse

Transcription of Pharmacy and Therapeutics Committee-approved …

1 Pharmacy and Therapeutics Committee-approvedTherapeutic InterchangesTherapeutic InterchangeRevision DateAlpha Blockers08/11 Alpha Reductase Inhibitors05/16 ACE Inhibitors08/11 Angiotensin Receptor Blockers08/11 Buprenorphine09/11 Calcium Channel Blockers (DHP)08/11 Carbapenems07/11 Cardioselective Beta Blockers08/11 Cephalosporins09/11 Corticosteroids, Inhaled06/16 Corticosteroids, Intranasal08/11 Fluoroquinolones01/13 Glitazones08/11 Histamine Receptor Antagonists (H2 RAs)08/11 Inhaled Anticholinergics05/16 Insulin Analogs05/16IV to PO conversions05/16 Leukotriene Receptor Antagonists08/11 Levalbuterol12/13 Miscellaneous Antidepressants05/16 Miscellaneous CNS Stimulants05/16 Nitroglycerin Sublingual05/16 Non-benzodiazepine Hypnotics08/11 Non-sedating Antihistamines08/11 Ophthalmic Preparations08/11 Phosphate Binders01/13 Proton Pump Inhbitors08/11 Statins08/11 All conversions unless noted otherwise are for adult patients with normal renal and/or hepatic function.

2 Please consult additional references when these clinical situations do not Peninsula Health System - MarquettePharmacy and Therapeutics Committee-approvedTherapeutic interchange : Alpha BlockersGeneric NameBrand NameTerazosinHytrin 1251020 DoxazosinCardura 124816 TamsulosinFlomax 1010N/AN/AN/A*Formulary agents in :Prazosin is not included in this therapeutic Equivalents (mg/day)Doxazosin and terazosin are therapeutically equivalent for the treatment of hypertension and benign prostatic hypertrophy (BPH).Alfuzosin and tamsulosin are therapeutically equivalent for the treatment of BPH and are the preferred agents in patients who are unable to tolerate the cardiovascular adverse effects from other alpha created: 08 : NoneUpper Peninsula Health System - MarquettePharmacy and Therapeutics Committee-approvedTherapeutic interchange : Alpha Reductase InhibitorsGeneric NameBrand NameFinasterideProscar DutasterideAvodart *Formulary agents in Equivalents (mg/day)5 mg once mg once dailyDocument created: 05 : NoneUpper Peninsula Health System - MarquettePharmacy and Therapeutics Committee-approvedTherapeutic interchange : ACE InhibitorsGeneric NameBrand NameShort-actingCaptoprilCapoten 75150300450 Intermediate-actingBenazeprilLotensin 5102040 EnalaprilVasotec 5102040 MoexiprilUnivasc 5102040 RamiprilAltace 5102040 FosinoprilMonopril 5102040 PerindoprilAceon 481216 TrandolaprilMavik 1248*Formulary agents in.

3 Captopril is short-acting and should be dosed 2-3 times is long-acting and should be dosed once Equivalents (mg/day)Enalapril and benazepril are intermediate-acting and should be dosed 1-2 times daily. Enalapril is the preferred intermediate-acting ACE inhibitor. Benazepril is available for continuation of outpatient created: 12 : 08 Peninsula Health System - MarquettePharmacy and Therapeutics Committee-approvedTherapeutic interchange : Angiotensin Receptor BlockersGeneric NameBrand NameLosartanCozaar 2550100100 CandesartanAtacand 481632 EprosartanTeveten 200400600800 IrbesartanAvapro 75150300300 OlmesartanBenicar 5102040 TelmisartanMicardis 20408080 ValsartanDiovan 4080160320*Formulary agent in Equivalents (mg/day)Document created: 08 : NoneUpper Peninsula Health System - MarquettePharmacy and Therapeutics Committee-approvedTherapeutic interchange : Buprenorphine SublingualGeneric NameBrand NameBuprenorphineSubutex 81624 Buprenorphine/naloxoneSuboxone 8/216/424/6*Formulary agent in :Dose Equivalents (mg/day)Suboxone strength expressed as buprenorphine/naloxone which are available as 2 mg and 8 mg/2 mg sublingual tablets and created: 09.

4 NoneUpper Peninsula Health System - MarquettePharmacy and Therapeutics Committee-approvedTherapeutic interchange : Calcium Channel Blockers (Dihydropyridines)Generic NameBrand NameAmlodipineNorvasc , extended releaseProcardia XL 306090 Felodipine, extended releasePlendil , immediate releaseDynaCirc 51020 Isradipine, controlled releaseDynaCirc CR 51020 Nicardipine, immediate releaseCardene 6090120 Nicardipine, controlled releaseCardene CR 6090120 Nisoldipine, extended releaseSular *Formulary agents in :Nimodipine (Nimotop ) is not subject to therapeutic Equivalents (mg/day)Amlodipine is the preferred dihydropyridine CCB. Nifedipine, extended release is available for continuation of outpatient created: 08 : NoneUpper Peninsula Health System - MarquettePharmacy and Therapeutics Committee-approvedTherapeutic interchange : CarbapenemsGeneric NameBrand NameMeropenemMerrem 20003000 DoripenemDoribax 15003000 Imipenem/cilastatinPrimaxin 20003000*Formulary agents in :Dose Equivalents (mg/day)The preferred dosing for the treatment of infections caused by multi-resistant gram negative bacilli or empiric therapy is meropenem 500 mg every 6 hours.

5 Please refer to the Carbapenem Guidelines for Use for further created: 07 : NoneUpper Peninsula Health System - MarquettePharmacy and Therapeutics Committee-approvedTherapeutic interchange : Cardioselective Beta BlockersGeneric NameBrand NameAtenololTenormin 2550100N/AMetoprololToprol 50100200400 BetaxololKerlone 1020N/AN/ABisoprololZebeta 51020N/ANebivololBystolic 5102040*Formulary agents in :Dose Equivalents (mg/day)Metoprolol is the preferred cardioselective beta blocker. Atenolol is available for continuation of outpatient created: 08 : NoneUpper Peninsula Health System - MarquettePharmacy and Therapeutics Committee-approvedTherapeutic interchange : CephalosporinsGeneric NameBrand NameCeftriaxoneRocephin 1000200030004000 CefotaximeClaforan 30006000900012000*Formulary agent in :Dose Equivalents (mg/day)Ceftriaxone is the preferred third generation cephalosporin in adult patients. Cefotaxime is available for use in neonates and for orders written by Infectious Diseases adult dosing for ceftriaxone is 1-2 gm every 12-24 hours (max: 4 gm/day), usual adult dosing for cefotaxime is 1-2 gm every 6-8 hours (max: 12 gm/day).

6 Document created: 09 : NoneUpper Peninsula Health System - MarquettePharmacy and Therapeutics Committee-approvedTherapeutic interchange : Corticosteroids, InhaledGeneric NameBrand NameBeclomethasone dipropionateQVAR 80 mcg12468 BudesonidePulmicort 180 mcg12 to 34 to 567+FluticasoneArnuity Ellipta 100 mcgFluticasoneArnuity Ellipta 200 mcgFluticasoneFlovent HFA 44 mcg1 to 34 to 67 to 89 to 1011+FluticasoneFlovent HFA 110 mcg12345+FluticasoneFlovent HFA 220 mcgN/A1N/A23+FluticasoneFlovent Diskus 50 mcg1 to 34 to 67 to 89 to 1011+FluticasoneFlovent Diskus 100 mcg12 to 3456+FluticasoneFlovent Diskus 250 mcgN/A1N/A23+MometasoneAsmanex 220 mcgN/A1234+*Formulary agent in NameBrand NameBudesonide/formoterolSymbicort 80 160 100/5 Mometasone/formoterolDulera 200/5 Fluticasone/vilanterolBreo Ellipta 100/25 Fluticasone/vilanterolBreo Ellipta 200/25 Fluticasone/salmeterolAdvair HFA 45/21 Fluticasone/salmeterolAdvair HFA 115/21 Fluticasone/salmeterolAdvair HFA 230/21 Fluticasone/salmeterolAdvair Diskus 100/50 Fluticasone/salmeterolAdvair Diskus 250/50

7 Fluticasone/salmeterolAdvair Diskus 500/50*Formulary agent in :Breo Ellipta (fluticasone/vilanterol) is indicated for asthma at one inhalation (100 mcg/25 mcg) once daily with maximum dosing of one inhalation (200 mcg/25 mcg) once daily and for COPD at one inhalation (100 mcg/25 mcg) once inhalation twice daily1 inhalation twice dailyN/A1 inhalation twice dailyN/AN/AN/AN/AN/A1 inhalation once daily1 inhalation once dailyN/A2 puffs twice dailyN/A2 puffs twice daily2 puffs twice daily2 puffs twice daily2 puffs twice dailyN/A2 puffs twice dailyN/A2 puffs twice dailyDose Equivalents (puffs per day)Dose Equivalents (puffs per day)1 inhalation once dailyN/A2 inhalations once dailyN/ADocument created: 01 : 01 Peninsula Health System - MarquettePharmacy and Therapeutics Committee-approvedTherapeutic interchange : Corticosteroids, IntranasalGeneric NameBrand NameDose EquivalentsFluticasone propionateFlonase 2 sprays in each nostril dailyBeclomethasoneBeconase AQ 1 to 2 sprays in each nostril twice dailyBudesonideRhinocort Aqua 1 spray in each nostril dailyCiclesonideOmnaris 2 sprays in each nostril dailyFlunisolideNasarel 2 sprays in each nostril 2 to 3 times dailyFluticasone furoateVeramyst 2 sprays in each nostril dailyMometasoneNasonex 2 sprays in each nostril dailyTriamcinoloneNasacort AQ 1 to 2 sprays in each nostril daily*Formulary agent in created: 01 : 08 Peninsula Health System - MarquettePharmacy and Therapeutics Committee-approvedTherapeutic interchange : FluoroquinolonesGeneric NameBrand NameIntravenousOralCiprofloxacinCipro Mild to moderate infections: 200 to 400 mg every 12 hoursSevere infections: 400 mg every 8 to 12 hoursMild to moderate infections: 250 to 500 mg every 12 hoursSevere infections.

8 500 to 750 mg every 8 to 12 hoursMoxifloxacinAvelox 400 mg every 24 hours400 mg every 24 hoursLevofloxacinLevaquin Mild to moderate infections: 250 to 500 mg every 24 hoursSevere infections: 500 to 750 mg every 24 hoursMild to moderate infections: 250 to 500 mg every 24 hoursSevere infections: 500 to 750 mg every 24 hoursOfloxacinFloxin N/A200 to 400 mg every 12 hoursNorfloxacinNoroxin N/A400 mg every 12 hoursGemifloxacinFactive N/A320 mg every 24 hours*Formulary agents in :Moxifloxacin should not be used for genitourinary infections and gram-negative Equivalents (mg/day)Document created: 05 : 01 Peninsula Health System - MarquettePharmacy and Therapeutics Committee-approvedTherapeutic interchange : Thiazolidinediones (Glitazones)Generic NameBrand NamePioglitazoneActos 153045 RosiglitazoneAvandia 248*Formulary agent in Equivalents (mg/day)Document created: 06 : 08 Peninsula Health System - MarquettePharmacy and Therapeutics Committee-approvedTherapeutic interchange : Histamine Receptor BlockersGeneric NameBrand NameFamotidine, oralPepcid 2040 CimetidineTagamet N/A600 to 1200 NizatidineAxid 150300 RanitidineZantac 150300 Famotidine, injectionPepcid IV 2040 CimetidineTagamet IV N/A900 to 1200 RanitidineZantac IV 50 to 100150 to 200*Formulary agent in Equivalents (mg/day)By declaration of the P&T Committee, the H2 RAs are subject to automatic IV to PO interchange .

9 Please refer to the Intravenous to Oral Medication Conversion Program for further created: 02 : 08 Peninsula Health System - MarquettePharmacy and Therapeutics Committee-approvedTherapeutic interchange : Inhaled AnticholinergicsGeneric NameBrand NameDose EquivalentsAlbuterol MDIV entolin 1-2 inhalations every 4-6 hoursAlbuterol nebulization solutionVentolin 1 vial three to four times per dayIpratropium nebulization solutionAtrovent 1 vial three to four times per dayIpratropium/albuterol nebulization solutionDuoNeb 1 vial four times per dayIpratropium/albuterol MDIC ombivent 2 inhalations four to six times per dayIpratropium MDIA trovent 2 inhalations four to six times per dayTiotropium inhalationSpiriva Respimat2 inhalations ( mcg each) once dailyTiotropium inhalationSpiriva Handihaler1 capsule once dailyAclidinium inhalationTudorza 1 inhalation twice dailyUmeclidinium inhalationIncruse 1 inhalation once daily*Formulary agents in.

10 DuoNeb contains ipratropium mg and albuterol 3 mg in each 3 mL unit-dose HandiHaler is to be used for administration of tiotropium which is dosed at 2 inhalations of a single 18 mcg capsule once Respimat inhaler contains ipratropium 20 mcg and albuterol 100 mcg in each inhalation (120 inhalations per cartridge).Combivent Respimat inhalers are not available for inpatient use at UPHSM. Non-ventilated patients may be switched to umeclidinium inhalation with or without an albuterol MDI (albuterol must be ordered separately) or to ipratropium/albuterol (DuoNeb ) nebulization solution. Ventilated patients may be switched to ipratropium/albuterol (DuoNeb ) nebulization metered dose inhalers (MDIs) are not available for inpatient use at UPHSM. Non-ventilated patients may be switched to umeclidinium inhalation or ipratropium (Atrovent ) nebulization solution. Ventilated patients may be switched to ipratropium (Atrovent ) nebulization and Spiriva inhalers may be switched to umeclidinium (Incruse ).


Related search queries